SG11202106700WA - Polypeptides comprising modified il-2 polypeptides and uses thereof - Google Patents
Polypeptides comprising modified il-2 polypeptides and uses thereofInfo
- Publication number
- SG11202106700WA SG11202106700WA SG11202106700WA SG11202106700WA SG11202106700WA SG 11202106700W A SG11202106700W A SG 11202106700WA SG 11202106700W A SG11202106700W A SG 11202106700WA SG 11202106700W A SG11202106700W A SG 11202106700WA SG 11202106700W A SG11202106700W A SG 11202106700WA
- Authority
- SG
- Singapore
- Prior art keywords
- polypeptides
- modified
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962789075P | 2019-01-07 | 2019-01-07 | |
PCT/US2020/012296 WO2020146221A1 (fr) | 2019-01-07 | 2020-01-06 | Polypeptides comprenant des polypeptides à il-2 modifiée et leurs utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202106700WA true SG11202106700WA (en) | 2021-07-29 |
Family
ID=69374426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202106700WA SG11202106700WA (en) | 2019-01-07 | 2020-01-06 | Polypeptides comprising modified il-2 polypeptides and uses thereof |
Country Status (15)
Country | Link |
---|---|
US (1) | US20220089667A1 (fr) |
EP (1) | EP3908596A1 (fr) |
JP (1) | JP2022516557A (fr) |
KR (1) | KR20210113265A (fr) |
CN (1) | CN113924311A (fr) |
AR (1) | AR117770A1 (fr) |
AU (1) | AU2020206672A1 (fr) |
BR (1) | BR112021012294A2 (fr) |
CA (1) | CA3125529A1 (fr) |
CL (1) | CL2021001779A1 (fr) |
IL (1) | IL284633A (fr) |
MX (1) | MX2021008147A (fr) |
SG (1) | SG11202106700WA (fr) |
TW (1) | TW202043259A (fr) |
WO (1) | WO2020146221A1 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019028425A1 (fr) | 2017-08-03 | 2019-02-07 | Synthorx, Inc. | Conjugués de cytokine pour le traitement de maladies auto-immunes |
CN111757745B (zh) | 2018-02-01 | 2022-11-04 | Nkmax有限公司 | 产生天然杀伤细胞的方法和用于治疗癌症的组合物 |
JP2023531876A (ja) * | 2020-06-30 | 2023-07-26 | ジーアイ イノベーション, インコーポレイテッド | 抗lag-3抗体とil-2とを含む融合タンパク質及びその使用 |
EP4175979A2 (fr) * | 2020-07-02 | 2023-05-10 | Inhibrx, Inc. | Polypeptides comprenant des polypeptides à il-2 modifiée et leurs utilisations |
CN112979782B (zh) * | 2021-03-08 | 2023-07-18 | 深圳市乐土生物医药有限公司 | 一种多肽及其用途 |
EP4314033A1 (fr) * | 2021-03-31 | 2024-02-07 | Anwita Biosciences, Inc. | Protéines de fusion, compositions pharmaceutiques et applications thérapeutiques |
TW202309102A (zh) * | 2021-07-20 | 2023-03-01 | 美商英伊布里克斯公司 | 靶向cd8之經修飾il-2多肽及其用途 |
EP4373854A1 (fr) * | 2021-07-20 | 2024-05-29 | Inhibrx, Inc. | Polypeptides se liant à cd8 et leurs utilisations |
CA3228815A1 (fr) * | 2021-08-30 | 2023-03-09 | John C. Timmer | Polypeptides se liant a nkp46 et leurs utilisations |
WO2023034741A1 (fr) * | 2021-08-30 | 2023-03-09 | Inhibrx, Inc. | Polypeptides il-2 modifiés ciblant nkp46 et leurs utilisations |
WO2023046156A1 (fr) * | 2021-09-26 | 2023-03-30 | Wuxi Biologics (Shanghai) Co. Ltd. | Variants d'il-2 et leurs protéines de fusion |
TW202334193A (zh) * | 2022-01-05 | 2023-09-01 | 美商英伊布里克斯公司 | 靶向γδ T細胞之經修飾IL-2多肽及其用途 |
WO2024026449A2 (fr) * | 2022-07-28 | 2024-02-01 | Proviva Therapeutics (Hong Kong) Limited | Protéines de fusion d'anticorps de procytokine il-2 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
IL136544A0 (en) | 1997-12-05 | 2001-06-14 | Scripps Research Inst | Humanization of murine antibody |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
NZ547279A (en) | 2003-10-22 | 2008-04-30 | Keck Graduate Inst | Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy |
AU2005227263A1 (en) * | 2004-03-05 | 2005-10-06 | Novartis Vaccines And Diagnostics, Inc. | In vitro test system for predicting patient tolerability of therapeutic agents |
CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
MXPA06011199A (es) | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
CN102101885B (zh) * | 2010-09-01 | 2013-06-05 | 南京发士达生物科技有限公司 | 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途 |
SI2673294T1 (sl) * | 2011-02-10 | 2016-08-31 | Roche Glycart Ag | Mutirani polipeptidi interlevkina-2 |
JP6306201B2 (ja) * | 2014-02-06 | 2018-04-04 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | インターロイキン−2融合タンパク質及びその使用 |
WO2016164937A2 (fr) * | 2015-04-10 | 2016-10-13 | Amgen Inc. | Mutéines de l'interleukine-2 pour l'expansion de lymphocytes t régulateurs |
JP2020521452A (ja) * | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
-
2020
- 2020-01-06 CA CA3125529A patent/CA3125529A1/fr active Pending
- 2020-01-06 AU AU2020206672A patent/AU2020206672A1/en active Pending
- 2020-01-06 US US17/418,458 patent/US20220089667A1/en active Pending
- 2020-01-06 KR KR1020217024431A patent/KR20210113265A/ko unknown
- 2020-01-06 MX MX2021008147A patent/MX2021008147A/es unknown
- 2020-01-06 WO PCT/US2020/012296 patent/WO2020146221A1/fr unknown
- 2020-01-06 CN CN202080018011.6A patent/CN113924311A/zh active Pending
- 2020-01-06 JP JP2021538982A patent/JP2022516557A/ja active Pending
- 2020-01-06 TW TW109100336A patent/TW202043259A/zh unknown
- 2020-01-06 SG SG11202106700WA patent/SG11202106700WA/en unknown
- 2020-01-06 BR BR112021012294-0A patent/BR112021012294A2/pt unknown
- 2020-01-06 EP EP20702547.9A patent/EP3908596A1/fr active Pending
- 2020-01-06 AR ARP200100028A patent/AR117770A1/es unknown
-
2021
- 2021-07-05 IL IL284633A patent/IL284633A/en unknown
- 2021-07-05 CL CL2021001779A patent/CL2021001779A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW202043259A (zh) | 2020-12-01 |
MX2021008147A (es) | 2021-08-11 |
AR117770A1 (es) | 2021-08-25 |
CL2021001779A1 (es) | 2022-03-04 |
WO2020146221A1 (fr) | 2020-07-16 |
IL284633A (en) | 2021-08-31 |
EP3908596A1 (fr) | 2021-11-17 |
AU2020206672A1 (en) | 2021-07-15 |
CN113924311A (zh) | 2022-01-11 |
CA3125529A1 (fr) | 2020-07-16 |
JP2022516557A (ja) | 2022-02-28 |
BR112021012294A2 (pt) | 2021-09-08 |
KR20210113265A (ko) | 2021-09-15 |
US20220089667A1 (en) | 2022-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL284633A (en) | Polypeptides containing modified IL-2 peptides and uses thereof | |
IL281192A (en) | Interleukin-2 polypeptide conjugates and uses thereof | |
IL274844A (en) | IL-2 mutants and their uses | |
IL287781A (en) | Clec-12a binding polypeptides and uses thereof | |
EP4076448A4 (fr) | Oxadiazoles fluoroalkylés et leurs utilisations | |
IL287782A (en) | 33cd-binding polypeptides and their uses | |
IL280808A (en) | OX40-binding polypeptides and their uses | |
EP3813861A4 (fr) | Polypeptides associés à l'héparine et leurs utilisations | |
GB201819200D0 (en) | Polypeptide and uses thereof | |
EP4081241A4 (fr) | Polypeptides régénératifs et leurs utilisations | |
SG11202006669RA (en) | Peptides and uses thereof | |
EP3816186A4 (fr) | Polypeptide se liant au pd-l1 et son utilisation | |
GB2603645B (en) | Polypeptides having anti-senescent effects and uses thereof | |
GB202201001D0 (en) | Polypeptide and use thereof | |
EP3630795C0 (fr) | Polypeptides aldolase modifiés et leurs utilisations | |
EP3684796A4 (fr) | Polypeptides régulateurs de succinate et utilisation associée | |
EP4103586A4 (fr) | Polypeptides et leur utilisation | |
EP3976630A4 (fr) | Protéines de liaison à actrii et leurs utilisations | |
GB2582571B (en) | Peptides and use thereof | |
GB202109082D0 (en) | Polypeptides and uses thereof | |
GB202018733D0 (en) | Polypeptides and uses thereof | |
GB201812328D0 (en) | Polypeptides and uses thereof | |
AU2019903255A0 (en) | Polypeptides and uses thereof | |
AU2018904117A0 (en) | Polypeptides and uses thereof | |
IL309885A (en) | Alpha-surface polypeptides and their use |